Event Date/Time: Nov 29, 2010 | End Date/Time: Dec 01, 2010 |
Registration Date: Nov 29, 2010 | |
Early Registration Date: Sep 10, 2010 |
Description
The 6th annual European Antibody Congress is the World’s leading conference addressing critical scientific issues and strategic industry challenges associated with therapeutic mAb development.
New for 2010
* New market success stories: golimumab, canakinumab, obatumumab, farletuzmab and girentuximab case studies
* For the first time on the agenda: Amgen, the FDA, Chugai Pharmaceutical Co, sanofi-aventis, Sandoz, Merrimack * Pharmaceuticals, AdAlta, Wilex, Vaccinex and Biocon
* First ever discussion of global biosimilar antibody development and impact on the European market
* Exploring radio-immunoconjugates: scientific, technical, regulatory and logistical challenges
* Spectacular boat cruise on board Lake Geneva
2010 key speakers include:
* Dr Andrew Goodearl, Director Bioresearch Center, Abbott Laboratories
* Dr Veronique Blanc, Head of Cancer Biology, Biologics, sanofi-aventis
* Dr Andrew Erdman, Global Safety Medical Director, Amgen
* Dr Mark McCamish, Head Global Pharmaceutical Development, Sandoz
* Dr Clive Wood, Senior Vice President and Head of Global Biologics, Bayer Schering Pharma
* Dr Alain Beck, Head of Physico-Chemistry Department, Centre d’Immunology Pierre Fabre
* Dr Scott Glaser, Director, Antibody Therapeutics, Biogen Idec
* Dr Sandeep Kumar, Principal Scientist, Global Biologics Pharmaceutical Sciences R&D, Pfizer Global R&D
* Dr Victor Obungu, Senior Research Scientist, Biotechnology Discovery Research, Eli Lilly & Co
* Dr Pablo Umana, Head of Research, Roche Glycart
Please visit the website for full programme and speaker details. www.terrapinn.com/antibodies